Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design
about
Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine developmentCrystal structure of measles virus hemagglutinin provides insight into effective vaccinesHIV-1 neutralizing antibodies: understanding nature's pathwaysAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinA directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinRapid profiling of the antigen regions recognized by serum antibodies using massively parallel sequencing of antigen-specific librariesHuman Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B EnvelopeHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesProgress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles.Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes.HIV-1 and influenza antibodies: seeing antigens in new waysNeutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technologyEngineering filamentous phage carriers to improve focusing of antibody responses against peptides.Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.Rational antibody-based HIV-1 vaccine design: current approaches and future directionsComparing antigenicity and immunogenicity of engineered gp120.Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvantsStructure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeastRecombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbsHyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaquesStructure-based vaccine design in HIV: blind men and the elephant?Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloIdentification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies.Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.Computational prediction of N-linked glycosylation incorporating structural properties and patterns.Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread.Antiviral antibody responses: the two extremes of a wide spectrum.Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infectionAntigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine DesignThe membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine designAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.Inhibition of HIV-1 entry by antibodies: potential viral and cellular targetsDesign of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies.Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene
P2860
Q21558777-33BB7CE2-E64D-427C-8C7C-0F7B13B75DECQ24669991-D93137D1-3D3F-4A83-9B41-D04AA0310A0AQ27000480-5D48D668-B307-468A-ACA0-268340712299Q27489000-A4ED7398-B908-4B9E-B280-4F48257ACF6CQ27675260-5954B3B1-9813-4959-8EAE-93EC3E463D1EQ28732438-29C10C1E-1CBE-4402-99AF-4E7192DFE808Q28743092-EB3E58D2-73E5-41B5-82FF-95255A41CCBDQ29048193-D07FB107-D01A-4980-BE0D-77078F4FB91BQ29307502-D21A8F44-5F27-49AC-B1EE-E21932410601Q29619015-BBA83C2F-8DC1-45E6-8058-D801AE881479Q30379200-CD2AE8EE-4F8E-4594-82D9-B4CB6980AA87Q30418340-EA84870A-4D84-4BB5-8438-D3A9FBC1D869Q33520582-404E52CB-1D3A-4DCF-BD39-D11161D25A66Q33552488-0A87AB8F-694C-4AC1-B964-0384857D41C3Q33688229-7BF505B5-3C8D-4DAD-A886-731B38E828B5Q33695321-9E235FF8-1342-4E72-B905-C8B5FE09B459Q33717477-174B3B78-6394-47A1-B98B-9EDAB4495FF3Q33883936-4491CAEE-9086-45AA-B418-C2B4C8482508Q33937285-5D74647F-41E1-4AB1-B4FA-AE5FAA6C829EQ33984309-336625D6-CB57-42C9-BCC8-CAEA1182E841Q34302085-DCDFF8E1-D17E-48D1-B5DF-683BA9007DBDQ34348303-72C0B458-0B22-479C-A27F-92B158E6C5BFQ34480254-57669804-CBD2-4BCB-AA33-D66C2F49ECDBQ34539819-289DC507-0346-4AA2-B9D2-C74F875537CFQ34594905-358237B7-003C-4546-9D7B-453D97C14DDEQ34663118-9811F1BA-727F-499A-A2D5-89668C2187EEQ34987048-84BA06E2-561C-4030-863C-AE46A68AEA7DQ35024202-80B03F1B-5054-4687-986C-1F5942BB6CB7Q35641314-3E5C24B1-6AC7-4136-B735-637C0D32E752Q35666057-05C750FB-5CD1-4914-865A-E4712F9B9717Q36186607-FE8FBF59-3F9D-4956-B525-F509E36A1F0DQ36228781-99C76088-E5A5-48D6-9337-6AADEE28B120Q36405084-0936D5B0-8A8F-496E-805E-35FCBC6712F3Q36423897-21EDAB68-CE9A-4818-B922-B70DFA6E27CFQ36447540-FE5E9507-6A25-4B19-B443-B803DDE65487Q36497712-6F1AE2CF-C148-46DA-BB5A-FE139E030D0AQ36600380-97EF514D-C6BD-4DCB-B7DF-3779041F2AC0Q36631937-6623E915-4D55-407A-A2CA-CBF124266C2BQ36742228-B94EBCB3-1BD5-4BFF-8DE1-C135F84112ADQ36931790-F3335FEF-5670-4793-875E-6FDC6B2595D9
P2860
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Hyperglycosylated mutants of h ...... ntigens for HIV vaccine design
@ast
Hyperglycosylated mutants of h ...... ntigens for HIV vaccine design
@en
Hyperglycosylated mutants of h ...... ntigens for HIV vaccine design
@nl
type
label
Hyperglycosylated mutants of h ...... ntigens for HIV vaccine design
@ast
Hyperglycosylated mutants of h ...... ntigens for HIV vaccine design
@en
Hyperglycosylated mutants of h ...... ntigens for HIV vaccine design
@nl
prefLabel
Hyperglycosylated mutants of h ...... ntigens for HIV vaccine design
@ast
Hyperglycosylated mutants of h ...... ntigens for HIV vaccine design
@en
Hyperglycosylated mutants of h ...... ntigens for HIV vaccine design
@nl
P2860
P1433
P1476
Hyperglycosylated mutants of h ...... ntigens for HIV vaccine design
@en
P2093
Dennis R Burton
Ralph Pantophlet
P2860
P304
P356
10.1128/JVI.77.10.5889-5901.2003
P407
P577
2003-05-01T00:00:00Z